Anzeige
Mehr »
Samstag, 21.03.2026 - Börsentäglich über 12.000 News
Drohnen statt Panzer: Beginnt hier der nächste Milliarden-Superzyklus?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 899376 | ISIN: US5147661046 | Ticker-Symbol: LDE
Tradegate
20.03.26 | 14:07
3,580 Euro
+2,29 % +0,080
1-Jahres-Chart
LIFECORE BIOMEDICAL INC Chart 1 Jahr
5-Tage-Chart
LIFECORE BIOMEDICAL INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,4803,50020.03.
3,4003,56020.03.

Aktuelle News zur LIFECORE BIOMEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiLifecore Biomedical stellt strategische Neuausrichtung und Wachstumsziele vor4
DiLifecore Stock Sinks As Delayed Launches Push Growth Further Out3
MoLifecore targets 12% revenue CAGR through 2029 as midterm pipeline milestones shift3
LIFECORE BIOMEDICAL Aktie jetzt für 0€ handeln
MoLifecore Biomedical: EPS verfehlt Schätzungen - Umsatz schlechter als erwartet4
MoLifecore Biomedical GAAP EPS of -$0.16, revenue of $35.75M5
MoLIFECORE BIOMEDICAL, INC. \DE\ - 8-K, Current Report1
10.03.Lifecore Biomedical, Inc.: Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum1
09.03.Lifecore Biomedical, Inc.: Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 20261
05.03.LIFECORE BIOMEDICAL, INC. \DE\ - 8-K, Current Report1
04.03.Lifecore to manufacture acne treatment batches for Indomo1
04.03.Lifecore übernimmt Herstellung von Akne-Wirkstoff für Indomo2
04.03.Lifecore Biomedical, Inc.: Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment523Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen, its Proprietary Intradermal Self-Injection Device Lifecore to Manufacture Drug...
► Artikel lesen
17.02.Lifecore Biomedical, Inc.: Lifecore Biomedical to Participate at DCAT Week 20262
16.01.Lifecore Biomedical, Inc.: Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)1
16.01.LIFECORE BIOMEDICAL, INC. \DE\ - 8-K, Current Report1
13.01.Grabar Law Office: Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Settles363Philadelphia, Pennsylvania--(Newsfile Corp. - January 13, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) as a securities...
► Artikel lesen
08.01.Grabar Law Office: Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Reaches Settlement1.828Philadelphia, Pennsylvania--(Newsfile Corp. - January 8, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) The investigation...
► Artikel lesen
30.12.25Grabar Law Office: Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Reaches Settlement2.544Philadelphia, Pennsylvania--(Newsfile Corp. - December 30, 2025) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) The investigation...
► Artikel lesen
29.12.25KeyBanc maintains Sector Weight rating on Lifecore Biomedical stock3
18.12.25Lifecore Biomedical, Inc.: Lifecore Biomedical to be Added to Nasdaq Biotech Index192CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced...
► Artikel lesen
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1